The company develops and commercializes product candidates for orphan and niche indications. It markets and sells its products in the United States, Europe, and other regions. The company targets pharmaceutical markets and seeks to recruit adequate patient numbers for clinical trials. It also focuses on commercialization, marketing, and manufacturing strategies to support these markets.

News about Xbiotech Inc Contracts

Healthcare Workforce Management Market Hits $1.7B in 2024, Surging to $2.8B by 2029 with a 10.1% CAGR | MarketsandMar...

Revolutionizing Healthcare Workforce Management: Market to Reach $2.8B by 2029 The healthcare workforce management systems market has shown remarkable growth over recent years, with projections indicating substantial future expansion. In 2024, the market valuation reached $1.7 billion and is anticipated to soar to $2.8 billion by 2029. This growth translates to a significant Compound Annual Growth Rate (CAGR) of 10.1% over the forecast period. These systems, essential for managing the diverse and dynamic needs of healthcare professionals, have become increasingly sophisticated and prevalent, particularly among leading healthcare organizations. Market Consolidation and Key PlayersThe healthcare workforce man...

XBiotechs Innovative Combination Therapy Shows Potential Breakthrough in Advanced Pancreatic Cancer Treatment ...

Potential Breakthrough in Pancreatic Cancer Treatment Emerges from XBiotech s Phase 1/2 StudyPancreatic cancer remains one of the most formidable oncological challenges, characterized by late-stage diagnosis and poor prognosis. However, a recent randomized double-blinded Phase 1/2 study conducted by XBiotech has yielded results that hint at a promising advancement in treating this deadly disease. The combination of ONIVYDE and 5-FU treatment with targeted anti-IL-1alpha therapy has shown not only potential therapeutic efficacy but also reduced toxicities, presenting a beacon of hope for patients with advanced pancreatic cancer. The Study and Its Promising ResultsThe study aimed to evaluate the efficacy and ...

Xbiotech Inc’s Comment on Sales, Marketing and Customers

XBIT's Stock Performance relative to it's Customers

XBIT's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Xbiotech Inc	66.77	8.21	-40.16	85
SUBTOTAL	0.00	0.00	0.00	-

Sources: Xbiotech Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Xbiotech Inc’s corporate clients.
For your research, we’ve provided 9 tables on Xbiotech Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.